鱼跃医疗(002223) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥1,661,551,525.50, representing a 19.45% increase compared to ¥1,390,964,598.25 in the same period last year[3]. - Net profit attributable to shareholders for Q1 2021 was ¥459,300,986.21, up 20.04% from ¥382,627,990.81 in the previous year[3]. - The net profit after deducting non-recurring gains and losses was ¥439,430,245.93, reflecting a 20.09% increase from ¥365,914,777.89 year-on-year[3]. - Basic and diluted earnings per share for Q1 2021 were both ¥0.4582, an increase of 20.04% from ¥0.3817 in the previous year[3]. - Total operating revenue for Q1 2021 reached CNY 1,661,551,525.50, an increase of 19.5% compared to CNY 1,390,964,598.25 in the same period last year[27]. - Net profit for Q1 2021 was CNY 461,824,942.88, representing a 21.4% increase from CNY 380,593,790.95 in Q1 2020[29]. - The company achieved an operating profit of CNY 526,023,824.86, an increase from CNY 441,366,202.87 in the previous year[29]. Cash Flow - The net cash flow from operating activities decreased significantly by 81.85%, amounting to ¥172,429,602.22 compared to ¥950,024,692.34 in the same period last year[3]. - The company reported a net cash flow from operating activities that decreased by 81.85% compared to the same period last year, attributed to the shift to regular credit and billing management[10]. - Cash inflow from operating activities totaled CNY 1,498,444,076.91, a decrease of 25.1% compared to CNY 1,999,214,752.85 in the previous year[35]. - Cash outflow from operating activities was CNY 1,326,014,474.69, an increase from CNY 1,049,190,060.51 in the same period last year[35]. - The net cash flow from investment activities was -CNY 615,511,899.14, an improvement from -CNY 1,035,956,431.41 year-over-year[35]. - The net cash flow from financing activities was -CNY 36,716,522.70, compared to a positive CNY 137,138,697.05 in the same period last year[36]. Assets and Liabilities - Total assets at the end of the reporting period were ¥9,962,696,155.43, a decrease of 1.02% from ¥10,065,252,420.67 at the end of the previous year[3]. - Total liabilities decreased from CNY 2,570,350,399.36 to CNY 2,360,252,818.53, a decrease of approximately 8.2%[23]. - Current liabilities decreased from CNY 2,329,906,407.85 to CNY 1,576,504,957.89, a decline of about 32.3%[23]. - Total current assets decreased to ¥4,984,455,276.42 from ¥5,334,996,095.33, indicating a reduction of approximately 6.6%[21]. - Total assets decreased from CNY 10,065,252,420.67 to CNY 9,962,696,155.43, a decline of approximately 1.03%[22]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 131,766[6]. - The largest shareholder, Jiangsu Yuyue Technology Development Co., Ltd., held 24.54% of the shares, totaling 245,983,450 shares[6]. - The company repurchased a total of 12,350,283 shares, accounting for 1.23% of the total share capital, with a total transaction amount of approximately 349.94 million yuan[11]. Investments and Expenses - Research and development expenses increased to CNY 72,224,167.63, up from CNY 66,682,612.95, reflecting a focus on innovation[28]. - Investment income increased by 47.15% compared to the same period last year, primarily due to increased returns from structured deposits[9]. - The company reported a tax expense of CNY 76,604,037.20, compared to CNY 72,343,045.69 in the same quarter last year[29]. - The company reported a 96.20% increase in taxes and surcharges compared to the same period last year, driven by increased sales performance[9]. Derivative and Risk Management - The company has no significant risks associated with its derivative positions as of the end of the reporting period[19]. - The company plans to conduct foreign exchange hedging business to mitigate market volatility risks, ensuring it does not affect normal operations[14]. - The company has not reported any non-compliance with external guarantees during the reporting period[19]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[19].